Observed Signal · Aug 11, 2026 · Product Selection · Source: https://martechseries.com/feed/ · Impact: 2/5 · Sentiment: Positive
Eli Lilly Selects Veeva Vault CRM Globally
Veeva Systems announced that Eli Lilly and Company has committed to Veeva Vault CRM for global deployment. Vault CRM, part of Veeva's Vault CRM Suite, is described as the technology foundation for “agentic commercial,” a commercial model that leverages AI to deliver medicines to patients. Giuseppe Firenze, senior vice president, U.S. HCP and field engagement hub at Lilly, and Veeva CEO Peter Gassner are quoted on the strategic expansion. Veeva is described as an industry cloud provider for life sciences serving more than 1,500 customers and operating as a Public Benefit Corporation. The announcement was distributed via PR Newswire and published on MarTech Series on August 11, 2026.
Enterprise CRM adoption by a major pharmaceutical company validates Veeva's Vault CRM in life sciences and signals continued investment in AI-enabled commercial systems, but it is a vendor customer win rather than an industry-wide policy or platform change.
Track Veeva Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Veeva Systems announced that Eli Lilly and Company has committed to Veeva Vault CRM globally.
- Vault CRM is part of the Vault CRM Suite and is positioned as the technology foundation for the 'agentic commercial' model that leverages AI.
- Giuseppe Firenze, senior vice president, U.S. HCP and field engagement hub at Lilly, said Vault CRM will help Lilly bring breakthrough medicines to more patients.
- Peter Gassner, CEO of Veeva, said Veeva is proud to expand strategic work with Lilly as they roll out Vault CRM globally.
- Veeva serves more than 1,500 customers and is a Public Benefit Corporation.
Connected Companies & Entities
5 Entities mapped“Veeva Systems announced that Eli Lilly and Company (Lilly) has committed to Veeva Vault CRM globally.”
“Veeva Systems announced that Eli Lilly and Company (Lilly) has committed to Veeva Vault CRM globally.”
“PR Newswire, a Cision company, is the premier global provider of multimedia platforms and distribution that marketers, corporate communicato...”
“MarTech Series is a leading publishing platform that provides daily updates on marketing technology news, in-depth interviews with industry ...”
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
10-Q Financial Filing Analysis for Veeva (2026-08-27)
Veeva Systems Inc. reported strong financial results for the second quarter of fiscal year 2027 ended July 31, 2026, with total revenue rising 18% year-over-year to $927.96 million. Top-line expansion was driven by a 16% increase in core subscription revenues to $766.76 million alongside a 24% rise in professional services to $161.20 million, driving GAAP operating income up to $275.02 million from $195.91 million in Q2 FY2026. Operationally, Veeva advanced its major migration of CRM customers from Salesforce to its proprietary Vault CRM platform (supported through 2029) and integrated Rise Healthcare Tech (Ostro), an AI-driven engagement platform acquired for $90 million, while deploying $246 million toward share repurchases.
IQVIA Expands Veeva Partnership with Clinical Operations Applications
IQVIA and Veeva Systems announced an expansion of their partnership, with IQVIA selecting Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications for its clinical development studies. This extends the previously announced EDC partnership. The collaboration aims to increase trial speed and efficiency, strengthen site centricity, and improve decision-making for clinical research customers. All Veeva clinical solutions will also be available through IQVIA for sponsors seeking a full Veeva technology stack. Executives from both companies emphasized the benefits of integrated technologies and customer flexibility in choosing EDC, RTSM, and eCOA solutions. The announcement was made on October 13, 2026, ahead of the Veeva R&D and Quality Summit scheduled for October 20-21 in Boston.
New Veeva Study Builder Agent to Configure Clinical Studies in as Little as One Day
Veeva announced the launch of its new Study Builder Agent, which enables the configuration of clinical studies in as little as one day. The announcement was published on September 24, 2026, highlighting a significant acceleration in clinical study setup timelines.
Receive all future signals for Veeva & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.